000			07024cam a2200757 i 4500
001			ocn893389733
003			OCoLC
005			20171026103811.0
006			m o d
007			cr |||||||||||
008			141017t20152015nju ob 001 0 eng
010			_a 2014041569
020			_a9781118788493 _q(ePub)
020			_a1118788494 _q(ePub)
020			_a9781118788547 _q(Adobe PDF)
020			_a1118788540 _q(Adobe PDF)
020			_a9781118788523 _q(ebook)
020			_a1118788524 _q(ebook)
020			_a9781322572406 _q(ebook)
020			_a1322572402 _q(ebook)
020			_z9781118788356 _q(hardback)
020			_z1118788354 _q(hardback)
029	1		_aCHDSB _b006372535
029	1		_aCHVBK _b333017153
029	1		_aDEBBG _bBV042795864
029	1		_aGBVCP _b819918776
029	1		_aDEBBG _bBV043397214
035			_a(OCoLC)893389733 _z(OCoLC)904539318 _z(OCoLC)960204304
037			_a688522 _bMIL
040			_aDLC _beng _erda _epn _cDLC _dN$T _dDG1 _dYDXCP _dE7B _dUWO _dCOO _dCDX _dOCLCQ _dOCLCO _dMMU _dDEBBG _dLOA _dKSU
042			_apcc
049			_aMAIN
050	0	0	_aRM315
060	1	0	_aWL 200
072		7	_aMED _x071000 _2bisacsh
082	0	0	_a615.7/8 _223
245	0	0	_aBlood-brain barrier in drug discovery : optimizing brain exposure of CNS drugs and minimizing brain side effects for peripheral drugs / _cedited by Li Di, Edward H. Kerns. _h[electronic resource]
246	3	0	_aOptimizing brain exposure of CNS drugs and minimizing brain side effects for peripheral drugs
264		1	_aHoboken, New Jersey : _bWiley, _c[2015]
264		4	_c©2015
300			_a1 online resource (xiv, 586 pages, 4 unnumbered pages of plates) : _billustrations (some color)
336			_atext _btxt _2rdacontent
336			_astill image _bsti _2rdacontent
337			_acomputer _bc _2rdamedia
338			_aonline resource _bcr _2rdacarrier
504			_aIncludes bibliographical references and index.
505	0		_aIntroduction and overview / Li Di, and Edward H. Kerns -- Part 1: Pharmacokinetics of brain exposure. Pharmacokinetics of CNS penetration / Andreas Reichel -- Free drug hypothesis for CNS drug candidates / Xingrong Liu and Cuiping Chen -- Species differences and impact of disease state on BBB / Jean-Marie Nicolas -- Part 2: Mechanisms of drugs across the blood-brain barrier. Passive diffusion permeability of the BBB: examples and SAR / Scott Summerfield, Phil Jeffrey, Jasminder Sahi, and Liangfu Chen -- Efflux transport at the BBB: examples and SAR / Jerome Hochman -- Establishment of P-glycoprotein structure-transport relationships to optimize CNS exposure in drug discovery / Jerome H. Hochman, Sookhee N. Ha, and Robert P. Sheridan -- Uptake transport at the BBB: examples and SAR / Ziquiang Cheng and Qian Liu -- Transport of protein and antibody therapeutics across the blood-brain barrier / William M. Pardridge -- Part 3: Predicting and measuring brain exposure of drugs. In silico tools for assessing brain exposure / Hongming Chen, Susanne Winiwarter, and Ola Engkvist -- In vitro assays for assessing BBB permeability: vascular cells, artificial membranes, brain slice, cell uptake / Alex Avdeef, Mária A. Deli, and Winfried Neuhaus -- Human-based in vitro endothelial cell models / Hannah K. Wilson and Eric Shusta -- Methods for assessing brain binding / Li Di and Cheng Chang -- In vivo studies of brain exposure in drug discovery / Edward H. Kerns -- PBPK modelling approach for predictions of human CNS drug brain distribution / Elizabeth C.M. de Lange -- PK/PD modeling of CNS drug candidates / Johan Gabrielsson, Stephan Hjorth, and Lambertus A. Peletier -- Microdialysis to assess free drug concentration in brain / William Kielbasa and Robert E. Stratford, Jr. -- Imaging techniques for central nervous system (CNS) drug discovery / Lei Zhang and Anabella Villalobos -- Part 4: Modulating brain penetration of leads during drug discovery. Designing CNS drugs for optimal brain exposure / Zoran Rankovic -- Case studies of CNS drug optimization: medicinal chemistry and CNS biology perspectives / Kevin J. Hodgetts -- Designing peripheral drugs for minimal brain exposure / Peter Bungay, Sharan Bagal, and Andy Pike -- Case studies of non-CNS drugs to minimize brain penetration: nonsedative antihistamines / Andrew Crowe -- Part 5: Case studies in CNS drug discovery. Case study 1: the discovery and development of perampanel / Antonio Laurenza, Jim Ferry, Haichen Yang, Shigeki Hibi, Takahisa Hanada, and Andrew Satlin -- Case study 2: the discovery and development of the multimodal acting antidepressant vortioxetine / Christoffer Bundgaard, Alan L. Pehrson, Connie Sánchez, and Benny Bang-Andersen -- Part 6: Drug delivery techniques to CNS. Brain delivery using nanotechnology / Huile Gao and Xinguo Jiang -- Intranasal delivery to the central nervous system / Lisbeth Illum -- Part 7: Future prospects in blood-brain barrier understanding and drug discovery. Future perspectives / N. Joan Abbott .
520			_a"Focused on central nervous system (CNS) drug discovery efforts, this book educates drug researchers about the blood-brain barrier (BBB) so they can affect important improvements in one of the most significant - and most challenging - areas of drug discovery. Written by world experts to provide practical solutions to increase brain penetration or minimize CNS side-effects. Reviews state-of-the-art in silico, in vitro, and in vivo tools to assess brain penetration and advanced CNS drug delivery strategies. Covers BBB physiology, medicinal chemistry design principles, free drug hypothesis for the BBB, and transport mechanisms including passive diffusion, uptake/efflux transporters, and receptor-mediated processes. Highlights the advances in modelling BBB pharmacokinetics and dynamics relationships (PK/PD) and physiologically-based pharmacokinetics (PBPK). Discusses case studies of successful CNS and non-CNS drugs, lessons learned and paths to the market"--Provided by publisher.
588			_aDescription based on online resource; title from PDF title page (ebrary, viewed May 9, 2016).
650		0	_aBlood-brain barrier _xMetabolism.
650		0	_aDrug development.
650		7	_aMEDICAL _xPharmacology. _2bisacsh
650	1	2	_aBlood-Brain Barrier _xmetabolism.
650	1	2	_aCentral Nervous System Agents _xpharmacokinetics.
650	2	2	_aBlood-Brain Barrier _xdrug effects.
650	2	2	_aCentral Nervous System Diseases _xdrug therapy.
650	2	2	_aDrug Discovery _xmethods.
650	2	2	_aDrug-Related Side Effects and Adverse Reactions _xprevention & control.
655		4	_aElectronic books.
655		0	_aElectronic books.
700	1		_aDi, Li, _eeditor.
700	1		_aKerns, Edward Harvel, _eeditor.
776	0	8	_iPrint version: _tBlood-brain barrier in drug discovery. _dHoboken, New Jersey : John Wiley & Sons Inc., [2015] _z9781118788356 _w(DLC) 2014040935 _w(OCoLC)889736023
856	4	0	_uhttp://onlinelibrary.wiley.com/book/10.1002/9781118788523 _zWiley Online Library
942			_2ddc _cBK
999			_c207715 _d207715